Top Story

Triptorelin, chemotherapy combination preserved long-term ovarian function

September 20, 2014

SAN FRANCISCO — Matteo Lambertini, MD, of the department of medical oncology at U.O. Oncologia Medica 2 in Italy, discusses long-term results of the PROMISE-GIM6 trial, which found that the addition of a luteinizing hormone-releasing analog to chemotherapy preserved long-term ovarian function in premenopausal women with early-stage breast cancer.

figure Meeting News CoverageVideo

Tumor subtype provided prognostic factor for survival after WBRT for metastatic breast cancer

September 19, 2014
SAN FRANCISCO — Vipin Das Villgran, MD, medical resident at University of Pittsburgh Medical Center, discusses study results which found that tumor subtype…

NIH director: Emerging biomedical research ‘breathtaking’

September 19, 2014
NIH director Francis Collins, MD, PhD, spoke to the audience at TEDMED 2014 about the advances in biomedical research on the horizon.“I have this amazing…
In the Journals

E-cigarettes emitted fewer carcinogenic particulates, higher toxic metals

September 19, 2014
Secondhand smoke from electronic cigarettes contained significantly fewer organic carcinogen emissions than tobacco-containing cigarettes, according to recent…
More News Headlines »
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Meeting News Coverage Video
figure

Triptorelin, chemotherapy combination preserved long-term ovarian function

September 20, 2014
SAN FRANCISCO — Matteo Lambertini, MD, of the department of medical oncology at U.O. Oncologia Medica 2 in…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »